Add to calendar

thursday 19 june 2014
hotel intercontinental,
one hamilton place,
park lane, w1j 7QY

Contact
The event organiser is Ford Sinclair Ltd.
Please contact Jo Thomas or Julia Peachey.

01277 350 557
jo.thomas@ford-sinclair.co.uk
julia.peachey@ford-sinclair.co.uk

2014 winners

1. Best Communication Award

Sponsored by Consilium Strategic Communications

Winner:
Evotec AG

Based in Hamburg, Germany, Evotec is a drug discovery solutions company providing drug discovery expertise and capabilities to pharmaceutical and biotechnology companies as well as to academic institutions. Evotec has been shortlisted in this category for each of the past three years, and that consistency of communication effectiveness is reflected in its shortlisting tonight.

It’s a prime concern of the company that all relevant target groups receive the same information at the same time, and this implies communicating in both English and German. All the company’s IR and Corporate Governance publications are available on its excellent website, while the annual report contains a link to an innovative “annual report in three minutes” video.

Evotec places great emphasis on a continual dialogue with financial analysts and investors. It conducts at least one analyst meeting every year and telephone conferences when quarterly financial results are published. In 2013, management presented the company at eleven national and international investor conferences and held a Capital Market Day in New York.

www.evotec.com

Winner of the Best Communication Award

Picture shows, left to right:
Erik Manting, Executive Director, Life Sciences and Health, Kempen & Co; Mary-Jane Elliott, Managing Partner, Consilium Strategic Communications; Gabriele Hansen, VP, Corporate Communications & Investor Relations, Evotec AG (winner); and Louise Minchin, awards presenter.

Click anywhere on the picture above to enlarge it.
Click below to download the photo:

High quality (approx. 2.9MB)

2. Breakthrough of the Year Award

Sponsored by Hume Brophy

Winner:
GW Pharmaceuticals plc

Based in Salisbury, Wiltshire, GW is developing a portfolio of cannabinoid medicines, including Sativex, for the treatment of MS spasticity and cancer pain, and Epidiolex for the treatment of childhood epilepsy.

Again, it’s been an active year for GW and there are a number of breakthroughs to choose from.

In June 2013 GW successfully raised $30m through a breakthrough IPO on NASDAQ. In January 2014 the company announced a successful follow-on offering, raising $101m to fund its Epidiolex® development programme for childhood epilepsy.

In November 2013 the company announced the FDA had granted orphan drug status for Epidiolex in the treatment of Dravet syndrome.

In February 2014 GW gained orphan drug designation from the FDA for Epidiolex® for use in treating children with Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy. Epidiolex is an oral liquid formulation of a highly purified extract of cannabidol CBD, a non-psychoactive molecule from the cannabis plant.

www.gwpharm.com

Winner of the Breakthrough of the Year Award

Picture shows, left to right:
Erik Manting, Executive Director, Life Sciences and Health, Kempen & Co; Geoffrey Guy, GW Pharmaceuticals plc (winner); Mary Clark, Managing Director, Healthcare, Hume Brophy; Justin Gover, GW Pharmaceuticals plc (winner); and Louise Minchin, awards presenter.

Click anywhere on the picture above to enlarge it.
Click below to download the photo:

High quality (approx. 3.0MB)

3. Best Technology Award

Sponsored by Design Portfolio

Winner:
Optos plc

Based in Scotland, Optos is a medtech company concentrating on retinal imaging, with a vision to be recognised as the leading provider of retinal diagnostics through leveraging its unique ultra-widefield imaging technology.

Its recently launched Daytona product represents the next generation of Optos ultra-widefield retinal imaging technology, and has been scaled to accommodate smaller office spaces while providing high resolution imaging. It weighs only 25kg and has been designed to increase patient comfort, as well as make it easier to correctly position the eye. Daytona features an improved user interface with intuitive software and “plug-n-play” installation.

Daytona was designed to allow the globalisation of the core Optos imaging technology, and to date, since launch just under two years ago, over 2,000 Daytona devices are in active use which now represents over 30% of the Optos installed client base, a figure which has been achieved from a standing start.

www.optos.com

Winner of the Best Technology Award

Picture shows, left to right:
Erik Manting, Executive Director, Life Sciences and Health, Kempen & Co; Jessica Coles, Head of Best Practice, Design Portfolio; David Wilson, Senior Non-executive Director, Optos plc (winner); and Louise Minchin, awards presenter.

Click anywhere on the picture above to enlarge it.
Click below to download the photo:

High quality (approx. 2.9MB)

4. Mediscience Commentator of the Year Award

Sponsored by Instinctif Partners

Winner:
John Carroll/FierceBiotech

John Carroll is a biotech analyst with 35 years of prize-winning experience in journalism. Aside from his daily industry coverage for FierceBiotech, where he was named editor in 2003, John has been a regular speaker at biotech events around the globe. He’s been a keynote speaker for several state associations, biotech groups in London and Cambridge, UK, addressed student audiences at MIT and Harvard and been quoted in The New Yorker, the Financial Times, the Boston Globe, New Scientist and other publications. John has covered genomics, biotechnology, healthcare and other business topics for American Banker, Managed Care and many other publications. He has contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press. He spent six years as editor and publisher of the Dallas Business Journal, was publisher of Texas Business and early in his career was part of a Pulitzer Prize-winning team of reporters and editors at the Kansas City Star & Times.

www.fiercebiotech.com

Winner of the Mediscience Commentator of the Year Award

Picture shows, left to right:
Erik Manting, Executive Director, Life Sciences and Health, Kempen & Co; Sue Charles, Managing Partner, Instinctif Partners; Tony Jones, One Nucleus (accepting the award on behalf of John Carroll, Editor, FierceBiotech) (winner); and Louise Minchin, awards presenter.

Click anywhere on the picture above to enlarge it.
Click below to download the photo:

High quality (approx. 4.6MB)

5. Transaction of the Year Award

Sponsored by Life Sciences Partners

Winner:
Ablynx NV

Based in Belgium, Ablynx has had an active 2013/14. On 26 September it extended its existing collaboration with Merck Serono through a multi-year research alliance that could lead to at least four co-discovery and co-development collaborations. Merck Serono will fund a dedicated discovery group at Ablynx, with both partners jointly selecting disease targets against which this group will develop Nanobodies, up to in-vivo proof-of-principle. This new alliance is an early stage discovery initiative, which allows the companies to rapidly explore the potential of novel targets across a range of therapeutic areas and to determine which programmes should be prioritised for later stage development. It is a very interesting model that could create substantial value for both parties in the future.

Further vindication of the Ablynx business model came just a few days earlier in September when Ablynx announced a global license agreement with AbbVie in respect of ALX-0061. This is Ablynx’s proprietary Nanobody that successfully completed a Phase IIa study in February 2013 reporting strong efficacy and safety data in patients with moderately to severely active rheumatoid arthritis (RA) on a stable background of methotrexate. Ablynx will receive an upfront payment of $175m, and on achievement of certain milestones, could receive further payments up to $665m plus royalties.

This is a major milestone for Ablynx and confirms both the potential value of ALX-0061 and the ability of Ablynx’s technology to generate clinical candidates with very exciting potential.

www.ablynx.com

Winner of the Transaction of the Year Award

Picture shows, left to right:
Erik Manting, Executive Director, Life Sciences and Health, Kempen & Co; Geraldine O’Keeffe, Partner, Life Sciences Partners; Ed Moses, CEO, Ablynx NV (winner); and Louise Minchin, awards presenter.

Click anywhere on the picture above to enlarge it.
Click below to download the photo:

High quality (approx. 2.9MB)

6. Most Significant Contribution to the Mediscience Sector Award

Sponsored by Shore Capital

Winner:
Jonathan Milner

Jonathan is the founder and CEO of Abcam, one of the leading biotech success stories to emanate from Cambridge. Jonathan has been very active in the life sciences industry for many years. Investing some £8m since 2005, mostly in healthcare companies, he has been involved in any number of initiatives.

Jonathan also sits on the advisory panel of Cambridge Innovation Capital – a new university fund for early stage companies that just raised £50m.

Winner of the Most Significant Contribution to the Mediscience Sector Award

Picture shows, left to right:
Erik Manting, Executive Director, Life Sciences and Health, Kempen & Co; Dr. Brian White, Shore Capital; Jonathan Milner (winner); and Louise Minchin, awards presenter.

Click anywhere on the picture above to enlarge it.
Click below to download the photo:

High quality (approx. 2.8MB)

7. Chief Executive of the Year Award

Sponsored by Panmure Gordon & Co

Winner:
Peter George/Clinigen Group plc

Based in Staffordshire, UK, Clinigen was formed in 2010 by the merger of three successful companies, namely Keats Healthcare, Clinigen Pharma and Clinigen. Peter became Group CEO at the time of the merger and has been responsible for devising and implementing the group’s growth strategy. He led the successful IPO process in September 2012 since when the group has continued to develop strongly, both organically and through carefully selected acquisitions.

Prior to joining Clinigen, Peter was the former CEO at Penn Pharma, having led a £67m management buy-out in 2007. Previously he was Executive VP for Wolters Kluwer Health with responsibility for Europe/Asia Pacific regions, and prior to that Peter was the Chief Operating Officer of Unilabs Clinical Trials International Limited.

www.clinigen.co.uk

Winner of the Chief Executive of the Year Award

Picture shows, left to right:
Erik Manting, Executive Director, Life Sciences and Health, Kempen & Co; Peter George, CEO, Clinigen Group plc (winner); Savvas Neophytou, Executive Director of Equity Research, Panmure Gordon & Co; and Louise Minchin, awards presenter.

Click anywhere on the picture above to enlarge it.
Click below to download the photo:

High quality (approx. 2.8MB)

8. The Emerging Star Award

Sponsored by Peel Hunt

Winner:
Horizon Discovery Group plc

Based in Cambridge, Horizon is the leading life science company supplying research tools to organisations engaged in genomics research and the development of personalised medicines. The company is a trusted supplier of genetically defined cell lines, reporter gene assay kits, genomic reference standards and contract research services to organisations engaged in biopharmaceutical process optimisation, drug discovery and development, and clinical diagnostic development.

Horizon had a very successful IPO on AIM in March, raising £68m in a placing at 180p and valuing the company at £120m. This is thought to be the largest fundraising on AIM from a mediscience company since AIM’s inception almost 20 years ago.

In the year to end December 2013 the company saw revenue growth of 70% to £6.6m with sales to 353 unique customers in 45 countries.

As a result of the IPO the company enters the next two years of its development with a very strong balance sheet that will be used to implement a business plan based on a world-leading gene editing and translational science base that should result in a leading position in translational genomics and personalised medicine.

www.horizondiscovery.com

Winner of The Emerging Star Award

Picture shows, left to right:
Erik Manting, Executive Director, Life Sciences and Health, Kempen & Co; James Steel, Corporate Director in the Healthcare and Life Sciences team, Peel Hunt; Paul Morrill, Senior Vice President, Reagent Products, Horizon Discovery Group plc (winner); Darrin Disley, CEO, Horizon Discovery Group plc (winner); Richard Vellacott, Senior Vice President, Finance & Operations, Horizon Discovery Group plc (winner); and Louise Minchin, awards presenter.

Click anywhere on the picture above to enlarge it.
Click below to download the photo:

High quality (approx. 3.0MB)

9. Company of the Year Award

Sponsored by Canaccord Genuity

Winner:
Swedish Orphan Biovitrum AB (SOBI)

Stockholm-based Sobi is an international specialty healthcare company dedicated to rare diseases. It has a diversified and growth-oriented commercial product portfolio with key therapeutic areas being Inflammation and Genetics and Metabolism, and three late stage biological development projects within Haemophilia and Neonatology. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing which have been validated by leading industry partners.

2013 was an eventful year for Sobi. Final results for the 12 months to end December 2013 showed total revenues up 13% at SEK 2,177m, product revenues up 16% at SEK 1,558m, and a gross margin improvement of 5 basis points to 59%.

Revenues in the fourth quarter alone rose 29%. Sobi also presented new data from its adult and paediatric haemophilia programmes with Biogen Idec, completed enrolment for its pivotal Kiobrina® Phase III trial, and announced new initiatives for Kepivance® in Head and Neck Cancer and for SOBI002, its novel biologic inhibitor of complement factor C5.

www.sobi.com

Winner of the Company of the Year Award

Picture shows, left to right:
Erik Manting, Executive Director, Life Sciences and Health, Kempen & Co; Dr. Julian Feneley, Head of Healthcare, Canaccord Genuity; Bruce Faulkner-Dunkley, SOBI (winner); and Louise Minchin, awards presenter.

Click anywhere on the picture above to enlarge it.
Click below to download the photo:

High quality (approx. 2.8MB)